Develops drugs for cardiometabolic and inflammatory diseases.
Sep 2024Revenue $16.9M/yrExpenses $53.1M/yr
No trendCash runway ≈ 11 months from Jun 2026
Figures by year
When will Veru be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Sep 2024, revenue was $16.9M and expenses $53.1M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Sep 2024 | $16.9M | $53.1M | −$36.2M |
| Sep 2023 | $16.3M | $110M | −$93.8M |
| Sep 2022 | $39.4M | $123M | −$83.5M |
| Sep 2021 | $61.3M | $48.3M | $13.0M |
| Sep 2020 | $42.6M | $57.3M | −$14.7M |
| Sep 2019 | $31.8M | $38.2M | −$6.44M |
| Sep 2018 | $15.9M | $36.7M | −$20.9M |
| Sep 2017 | $13.7M | $22.1M | −$8.49M |
| Sep 2016 | $22.1M | $19.1M | $3.02M |
| Sep 2015 | $32.6M | $26.0M | $6.62M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.